Cohort 2
Cohort 2 is an intervention with 7 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
1
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
1
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Identification and Description of Patients With High-risk Non Metastatic RCC
A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
Phase I Study of Safety and Immunogenicity of ADU-623
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)
Clinical Trials (7)
Identification and Description of Patients With High-risk Non Metastatic RCC
A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
Phase I Study of Safety and Immunogenicity of ADU-623
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)
A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism
A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function
All 7 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 7